Holen Sie sich die Stockscreener-App
18.44
2.90%
-0.55
Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
MoonLake Immunotherapeutics (MLTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
MoonLake Immunotherapeutics (MLTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MLTX|MoonLake Immunotherapeutics|Price:19.890|Chg%:+0.870 - TradingKey
TradingKey - TradingKey
MoonLake Immunotherapeutics (MLTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MLTX|MoonLake Immunotherapeutics|Price:19.020|Chg%:-0.340 - TradingKey
What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors - Kavout | AI
MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits
MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts - Stocktwits
MoonLake Immunotherapeutics CSO Kristian Reich disposes of $1 million in common shares - Bitget
Form 4 MoonLake Immunotherapeutics For: 21 July By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Moonlake stock buy rating on funding By Investing.com - Investing.com South Africa
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event - Stocktwits
H.C. Wainwright reiterates Moonlake stock buy rating on funding - Investing.com
Analyst Maintains Buy on MoonLake, Reiterates $45 Price Target on Strong Financing and Sonelokimab Commercial Potential - TipRanks
MoonLake Immunotherapeutics (NASDAQ: MLTX) CSO entity sells 16,105 shares - Stock Titan
MoonLake Immunotherapeutics CSO Kristian Reich sells 16,105 shares for $322,261.05 - Bitget
Behavioral Patterns of MLTX and Institutional Flows - Stock Traders Daily
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites - Stocktwits
MoonLake Immunotherapeutics (MLTX) Surges 4.6%: Key Levels to WatchETF NAV Deviation - dars.gov.et
MoonLake Immunotherapeutics prices $200M public offering of Class A shares - MSN
Moonlake Therapeutics raises USD 230 million in public offering - Startupticker.ch
Form 144 MoonLake Immunotherapeutics For: 15 July By Investing.com - Investing.com India
MoonLake Immunotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Jerucon plans 150,000-share MLTX sale in Form 144 (Nasdaq: MLTX) - Stock Titan
MoonLake Immunotherapeutics Announces Public Offering of Class A Shares on NASDAQ – 8-K Filing Details - Minichart
MoonLake Immunotherapeutics (NASDAQ: MLTX) raises $30M via option exercise - Stock Titan
Insider Sell: Santos da Silva Jorge Sells 102,225 Shares of Moon - GuruFocus
Insider Sell: Santos da Silva Jorge Sells 102,225 Shares of MoonLake Immunotherapeutics (MLTX) - GuruFocus
[Form 4] MoonLake Immunotherapeutics Insider Trading Activity - Stock Titan
SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears - Yahoo Finance
MoonLake Immunotherapeutics' CFO Sells 39K Shares - The Motley Fool
Insider Sell: Santos da Silva Jorge Sells 47,775 Shares of MoonL - GuruFocus
CEO of MoonLake Immunotherapeutics (NASDAQ: MLTX) sells shares under plan - Stock Titan
Class Action Lawsuit Filed Against MoonLake Immunotherapeutics (M - The National Law Review
MoonLake Reports Positive 52-Week Phase 3 Data for Sonelokimab in Hidradenitis Suppurativa - Dermatology Times
Top biotech stocks to watch in second half of 2026, says Clear Street - Investing.com South Africa
MLTX Maintained by Leerink Partners -- Price Target Raised to $2 - GuruFocus
Leerink raises Moonlake stock price target on HS drug data By Investing.com - Investing.com South Africa
Leerink raises Moonlake stock price target on HS drug data - Investing.com
Form 144 MoonLake Immunotherapeutics For: 30 June By Investing.com - Investing.com South Africa
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):